和黄医药呋喹替尼海外销售持续增长,ATTC研发顺利推进

国信证券
Mar 12

呋喹替尼海外销售持续增长,2026年收入指引积极。和黄医药2025年总市场销售额为5.25亿美元(+5%);其中呋喹替尼海外销售达3.66亿美元(+26%),增长主要由全球市场的拓展驱动。呋喹替尼中国销售1.00亿美元(-13%),其中25H2销售0.57亿美元,较25H1增长33%。2025年净利润为4.57亿美元,大幅增长主要得益于出售上海和黄药业45%股权确认收益4.16亿美元。截至2025...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10